- Tous > Medicine Information and Evidence for Policy > Medicines Policy
- Tous > Medicine Access and Rational Use > Pricing
- Mots-clés > drug pricing policy
- Mots-clés > fair pricing model for medicines
- Mots-clés > generic substitution policy - prices
- Mots-clés > innovation and access
- Mots-clés > medicine prices transparency
- Mots-clés > new medicines - prices, costs and affordability
- Mots-clés > price components
- Mots-clés > price regulation
- Mots-clés > prices / pricing policy
- Mots-clés > pricing system
(2017; 15 pages)
The main aim of the Forum, held on the 11th May 2017 in Amsterdam, was to enable stakeholders to discuss options for a fairer pricing system that is sustainable for both health systems and the pharmaceutical industries.
The Forum sought to address three questions:
- What can governments do to ensure fairer medicines prices and greater access?
- What can industry do?
- How can WHO support the process?
Key issues addressed included: developing alternative approaches for research and development (R&D) and business models for innovation; facilitating collaboration among payers by expanding current networks to include other relevant stakeholders and countries; increasing exchange of information, for example to assess the value of new products; promoting transparency of prices paid, R&D costs, production costs, and profit margins.
The Forum was hosted by the Dutch Ministry of Health, Welfare and Sport together with WHO, and attended by representatives from non-governmental and patient organizations and Member States (Annex A) and the pharmaceutical industry. The forum was divided into two parts – an interactive plenary session in the morning, based on a series of four short films addressing different aspects of the pricing/access issue, followed by breakout sessions in the afternoon covering related themes (Annex B).